Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony G Wilson

Showing results (61-70 of 120) with videos related to

Pageof 12
Sort By:
Pharmacogenetics and Genomics|March 6, 2009
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patientsJohn D Bowes, Catherine Potter, Laura J Gibbons, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
Arthritis and Rheumatism|August 1, 2008
Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factorInmaculada Rioja, Fiona J Hughes, Catriona H Sharp, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathwaysCatherine Potter, Heather J Cordell, Anne Barton, et al.
Rheumatology (Oxford, England)|October 3, 2022
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritisRyan M Hum, Pauline Ho, Nisha Nair, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 4, 2012
Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug classDonald L Bliwise, Lynn Marie Trotti, Anthony G Wilson, et al.
Annals of the Rheumatic Diseases|August 25, 2009
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive diseaseJames I Robinson, Jennifer H Barrett, John C Taylor, et al.
Rheumatology (Oxford, England)|June 30, 2023
A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measuresStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Pageof 12

Showing results (61-70 of 120) with videos related to

Sort By:
Pageof 12
Pharmacogenetics and Genomics|March 6, 2009
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patientsJohn D Bowes, Catherine Potter, Laura J Gibbons, et al.
Pharmacogenomics|October 30, 2020
Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity scoreSyed Sa Gilani, Nisha Nair, Darren Plant, et al.
Arthritis and Rheumatism|August 1, 2008
Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factorInmaculada Rioja, Fiona J Hughes, Catriona H Sharp, et al.
Annals of the Rheumatic Diseases|May 8, 2010
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathwaysCatherine Potter, Heather J Cordell, Anne Barton, et al.
Rheumatology (Oxford, England)|October 3, 2022
Non-trough adalimumab and certolizumab drug levels associated with a therapeutic EULAR response in adherent patients with rheumatoid arthritisRyan M Hum, Pauline Ho, Nisha Nair, et al.
The Pharmacogenomics Journal|September 1, 2018
Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritisJonathan Massey, Darren Plant, Kimme Hyrich, et al.
Lancet (London, England)|August 28, 2015
Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritisMeghna Jani, Hector Chinoy, Richard B Warren, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|July 4, 2012
Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug classDonald L Bliwise, Lynn Marie Trotti, Anthony G Wilson, et al.
Annals of the Rheumatic Diseases|August 25, 2009
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive diseaseJames I Robinson, Jennifer H Barrett, John C Taylor, et al.
Rheumatology (Oxford, England)|June 30, 2023
A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measuresStephanie F Ling, Chuan Fu Yap, Nisha Nair, et al.
Pageof 12